Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada

Background This study analyzed the health and economic outcomes of the 21-valent pneumococcal conjugate vaccine (PNEU-C-21; CAPVAXIVE®) compared to either PNEU-C-20 or PNEU-P-23. Cohorts in the cost-effectiveness analyses included vaccine-naïve 57- and 65-year-olds and vaccine-experienced 70-year-ol...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Peter P. Mueller, Marie-Claude Meilleur, Zinan Yi, Amanda Martino, Kwame Owusu-Edusei
Format:	Artigo
Sprog:	Inglês
Udgivet:	Taylor & Francis Group 2026-12-01
Serier:	Expert Review of Vaccines
Fag:	Pneumococcal infections pneumococcal vaccines PNEU-C-21 cost-effectiveness analysis comparative study community-acquired infections
Online adgang:	https://www.tandfonline.com/doi/10.1080/14760584.2025.2608811
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!